Chemiluminescence selectivity enhancement in the on-chip Ru(bpy)3 2+ system

The potential role of buffer type and pH in the determination of hydrochlorothiazide in combined formulations and human plasma

Afsal Mohammed Kadavilpparampu, Haider A.J. Al Lawati, Fakhr Eldin O. Suliman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A simple and highly selective on-chip Ru(bpy)3 2+-oxidant chemiluminescence (CL) approach for estimation of a diuretic drug, hydrochlorothiazide (HCZ), in biological fluids was realized in the presence of other fixed-dose combination drugs by manipulating simultaneously the method of active species (Ru(bpy)3 3+) production and type of carrier buffer with pH used for the CL reaction. Chemical oxidation processes involved in the Ru(bpy)3 2+-Ce(IV) CL system have been successfully miniaturised in this study using a microfabricated device to generate Ru(bpy)3 3+ instantaneously. The proposed system was then screened using HCZ and other drugs in the presence of various buffers and pH to explore the difference in CL emission. Ammonium formate buffer (0.15 M) at pH 4.5 exhibited excellent selectivity towards HCZ when Ru(bpy)3 3+ was produced by chemical oxidation using Ce(IV). The newly developed conditions do not involve any kind of prior separation or isolation procedure to remove other combination therapy drugs in formulation and biological samples. The method under fully optimised conditions exhibited wide linearity over the concentration range 0.5-1000 ng ml-1 and low detection and quantification limits of 0.13 and 0.47 ng ml-1 respectively for HCZ. Acceptable levels of recoveries were obtained for HCZ from human plasma using the proposed method (98.9-100.8%) in the presence of other antihypertensive combination therapy drugs. This study postulates that such miniaturised devices may find applications especially for on-site analysis, such as doping control examinations.

Original languageEnglish
JournalLuminescence
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Plasma (human)
Hydrochlorothiazide
Chemiluminescence
Luminescence
Buffers
Drug therapy
formic acid
Chemical Phenomena
Equipment and Supplies
Oxidation
Drug Compounding
Drug Combinations
Combination Drug Therapy
Diuretics
Oxidants
Pharmaceutical Preparations
Antihypertensive Agents
Limit of Detection
Doping (additives)
tris(2,2'-bipyridine)ruthenium II

Keywords

  • Chemical oxidation
  • Chemiluminescence
  • Hydrochlorothiazide
  • Microfluidic

ASJC Scopus subject areas

  • Chemistry (miscellaneous)
  • Biophysics

Cite this

@article{691fe8b1e8e64578a8b5da4029695d87,
title = "Chemiluminescence selectivity enhancement in the on-chip Ru(bpy)3 2+ system: The potential role of buffer type and pH in the determination of hydrochlorothiazide in combined formulations and human plasma",
abstract = "A simple and highly selective on-chip Ru(bpy)3 2+-oxidant chemiluminescence (CL) approach for estimation of a diuretic drug, hydrochlorothiazide (HCZ), in biological fluids was realized in the presence of other fixed-dose combination drugs by manipulating simultaneously the method of active species (Ru(bpy)3 3+) production and type of carrier buffer with pH used for the CL reaction. Chemical oxidation processes involved in the Ru(bpy)3 2+-Ce(IV) CL system have been successfully miniaturised in this study using a microfabricated device to generate Ru(bpy)3 3+ instantaneously. The proposed system was then screened using HCZ and other drugs in the presence of various buffers and pH to explore the difference in CL emission. Ammonium formate buffer (0.15 M) at pH 4.5 exhibited excellent selectivity towards HCZ when Ru(bpy)3 3+ was produced by chemical oxidation using Ce(IV). The newly developed conditions do not involve any kind of prior separation or isolation procedure to remove other combination therapy drugs in formulation and biological samples. The method under fully optimised conditions exhibited wide linearity over the concentration range 0.5-1000 ng ml-1 and low detection and quantification limits of 0.13 and 0.47 ng ml-1 respectively for HCZ. Acceptable levels of recoveries were obtained for HCZ from human plasma using the proposed method (98.9-100.8{\%}) in the presence of other antihypertensive combination therapy drugs. This study postulates that such miniaturised devices may find applications especially for on-site analysis, such as doping control examinations.",
keywords = "Chemical oxidation, Chemiluminescence, Hydrochlorothiazide, Microfluidic",
author = "Kadavilpparampu, {Afsal Mohammed} and {Al Lawati}, {Haider A.J.} and Suliman, {Fakhr Eldin O.}",
year = "2017",
doi = "10.1002/bio.3350",
language = "English",
journal = "Luminescence",
issn = "1522-7235",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Chemiluminescence selectivity enhancement in the on-chip Ru(bpy)3 2+ system

T2 - The potential role of buffer type and pH in the determination of hydrochlorothiazide in combined formulations and human plasma

AU - Kadavilpparampu, Afsal Mohammed

AU - Al Lawati, Haider A.J.

AU - Suliman, Fakhr Eldin O.

PY - 2017

Y1 - 2017

N2 - A simple and highly selective on-chip Ru(bpy)3 2+-oxidant chemiluminescence (CL) approach for estimation of a diuretic drug, hydrochlorothiazide (HCZ), in biological fluids was realized in the presence of other fixed-dose combination drugs by manipulating simultaneously the method of active species (Ru(bpy)3 3+) production and type of carrier buffer with pH used for the CL reaction. Chemical oxidation processes involved in the Ru(bpy)3 2+-Ce(IV) CL system have been successfully miniaturised in this study using a microfabricated device to generate Ru(bpy)3 3+ instantaneously. The proposed system was then screened using HCZ and other drugs in the presence of various buffers and pH to explore the difference in CL emission. Ammonium formate buffer (0.15 M) at pH 4.5 exhibited excellent selectivity towards HCZ when Ru(bpy)3 3+ was produced by chemical oxidation using Ce(IV). The newly developed conditions do not involve any kind of prior separation or isolation procedure to remove other combination therapy drugs in formulation and biological samples. The method under fully optimised conditions exhibited wide linearity over the concentration range 0.5-1000 ng ml-1 and low detection and quantification limits of 0.13 and 0.47 ng ml-1 respectively for HCZ. Acceptable levels of recoveries were obtained for HCZ from human plasma using the proposed method (98.9-100.8%) in the presence of other antihypertensive combination therapy drugs. This study postulates that such miniaturised devices may find applications especially for on-site analysis, such as doping control examinations.

AB - A simple and highly selective on-chip Ru(bpy)3 2+-oxidant chemiluminescence (CL) approach for estimation of a diuretic drug, hydrochlorothiazide (HCZ), in biological fluids was realized in the presence of other fixed-dose combination drugs by manipulating simultaneously the method of active species (Ru(bpy)3 3+) production and type of carrier buffer with pH used for the CL reaction. Chemical oxidation processes involved in the Ru(bpy)3 2+-Ce(IV) CL system have been successfully miniaturised in this study using a microfabricated device to generate Ru(bpy)3 3+ instantaneously. The proposed system was then screened using HCZ and other drugs in the presence of various buffers and pH to explore the difference in CL emission. Ammonium formate buffer (0.15 M) at pH 4.5 exhibited excellent selectivity towards HCZ when Ru(bpy)3 3+ was produced by chemical oxidation using Ce(IV). The newly developed conditions do not involve any kind of prior separation or isolation procedure to remove other combination therapy drugs in formulation and biological samples. The method under fully optimised conditions exhibited wide linearity over the concentration range 0.5-1000 ng ml-1 and low detection and quantification limits of 0.13 and 0.47 ng ml-1 respectively for HCZ. Acceptable levels of recoveries were obtained for HCZ from human plasma using the proposed method (98.9-100.8%) in the presence of other antihypertensive combination therapy drugs. This study postulates that such miniaturised devices may find applications especially for on-site analysis, such as doping control examinations.

KW - Chemical oxidation

KW - Chemiluminescence

KW - Hydrochlorothiazide

KW - Microfluidic

UR - http://www.scopus.com/inward/record.url?scp=85020628695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020628695&partnerID=8YFLogxK

U2 - 10.1002/bio.3350

DO - 10.1002/bio.3350

M3 - Article

JO - Luminescence

JF - Luminescence

SN - 1522-7235

ER -